JP2015511958A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511958A5
JP2015511958A5 JP2014560985A JP2014560985A JP2015511958A5 JP 2015511958 A5 JP2015511958 A5 JP 2015511958A5 JP 2014560985 A JP2014560985 A JP 2014560985A JP 2014560985 A JP2014560985 A JP 2014560985A JP 2015511958 A5 JP2015511958 A5 JP 2015511958A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutically acceptable
compound
acceptable salt
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560985A
Other languages
English (en)
Japanese (ja)
Other versions
JP6161643B2 (ja
JP2015511958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/028796 external-priority patent/WO2013134085A1/en
Publication of JP2015511958A publication Critical patent/JP2015511958A/ja
Publication of JP2015511958A5 publication Critical patent/JP2015511958A5/ja
Application granted granted Critical
Publication of JP6161643B2 publication Critical patent/JP6161643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560985A 2012-03-05 2013-03-04 β−セクレターゼ阻害剤 Expired - Fee Related JP6161643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606786P 2012-03-05 2012-03-05
US61/606,786 2012-03-05
PCT/US2013/028796 WO2013134085A1 (en) 2012-03-05 2013-03-04 Inhibitors of beta-secretase

Publications (3)

Publication Number Publication Date
JP2015511958A JP2015511958A (ja) 2015-04-23
JP2015511958A5 true JP2015511958A5 (OSRAM) 2016-04-21
JP6161643B2 JP6161643B2 (ja) 2017-07-12

Family

ID=47902355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560985A Expired - Fee Related JP6161643B2 (ja) 2012-03-05 2013-03-04 β−セクレターゼ阻害剤

Country Status (39)

Country Link
US (4) US8981112B2 (OSRAM)
EP (1) EP2822930B1 (OSRAM)
JP (1) JP6161643B2 (OSRAM)
KR (1) KR20140138774A (OSRAM)
CN (1) CN104271558B (OSRAM)
AP (1) AP4029A (OSRAM)
AR (1) AR090241A1 (OSRAM)
AU (2) AU2013230523B2 (OSRAM)
BR (1) BR112014021269A2 (OSRAM)
CA (1) CA2864143C (OSRAM)
CL (1) CL2014002334A1 (OSRAM)
CO (1) CO7091177A2 (OSRAM)
CY (1) CY1117543T1 (OSRAM)
DK (1) DK2822930T3 (OSRAM)
EA (1) EA024995B1 (OSRAM)
EC (1) ECSP14020640A (OSRAM)
ES (1) ES2568928T3 (OSRAM)
HR (1) HRP20160415T1 (OSRAM)
HU (1) HUE027289T2 (OSRAM)
IL (1) IL233887A (OSRAM)
IN (1) IN2014DN06710A (OSRAM)
MA (1) MA35945B1 (OSRAM)
ME (1) ME02390B (OSRAM)
MX (1) MX353432B (OSRAM)
MY (1) MY171091A (OSRAM)
NZ (1) NZ629239A (OSRAM)
PE (1) PE20141972A1 (OSRAM)
PH (1) PH12014501963B1 (OSRAM)
PL (1) PL2822930T3 (OSRAM)
RS (1) RS54730B1 (OSRAM)
SG (1) SG11201404600VA (OSRAM)
SI (1) SI2822930T1 (OSRAM)
SM (1) SMT201600114B (OSRAM)
TN (1) TN2014000326A1 (OSRAM)
TW (1) TWI557112B (OSRAM)
UA (1) UA113641C2 (OSRAM)
UY (1) UY34654A (OSRAM)
WO (1) WO2013134085A1 (OSRAM)
ZA (1) ZA201405846B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2789684T3 (en) 2008-05-23 2017-02-20 Siwa Corp Methods and compositions for facilitating regeneration
MX2011009571A (es) 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
WO2011106414A1 (en) 2010-02-24 2011-09-01 Dillard Lawrence W Inhibitors of beta-secretase
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β-分泌酶抑制劑
WO2013169531A1 (en) 2012-05-09 2013-11-14 Boehringer Ingelheim International Gmbh Methods for making oxetan-3-ylmethanamines
TW201422592A (zh) * 2012-08-27 2014-06-16 Boehringer Ingelheim Int β-分泌酶抑制劑
JP2015532282A (ja) 2012-09-28 2015-11-09 ヴァイティー ファーマシューティカルズ,インコーポレイテッド β−セクレターゼの阻害剤
EP2922835B1 (en) 2012-11-21 2017-08-09 Boehringer Ingelheim International GmbH Process for making n-sulfinyl alpha-amino amides
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
EP4067386A1 (en) 2016-02-19 2022-10-05 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
CA3039026A1 (en) * 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3946606B1 (en) 2019-03-27 2025-01-01 Insilico Medicine IP Limited Bicyclic jak inhibitors and uses thereof
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
BE1027699B1 (fr) * 2021-01-28 2022-04-01 Trasis S A Procédé de purification de macro-agrégats de sérumalbumine humaine radiomarqués
CN113082209A (zh) * 2021-03-31 2021-07-09 中国科学技术大学 Cd4+t细胞源性bace1、ep2、ep4作为阿尔茨海默病治疗靶点的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
AU655666B2 (en) 1991-08-28 1995-01-05 Pharmacia & Upjohn Company Spirocyclic benzopyran imidazolines
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2153832B1 (en) 2003-12-15 2016-03-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2008503460A (ja) 2004-06-16 2008-02-07 ワイス β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
BRPI0512213A (pt) 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
CA2583342A1 (en) 2004-10-13 2006-04-27 Merck And Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease
AR054619A1 (es) 2005-06-14 2007-07-04 Schering Corp Inhibidores de aspartil proteasas
JP2008543840A (ja) 2005-06-14 2008-12-04 シェーリング コーポレイション アスパルチルプロテアーゼインヒビター
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
CN101213183A (zh) 2005-06-30 2008-07-02 惠氏公司 氨基-5-(6元)杂芳基咪唑酮化合物和在β-分泌酶调节中的用途
WO2007013002A2 (en) 2005-07-29 2007-02-01 Koninklijke Philips Electronics N.V. Method for generating a burst of steam from a steam iron
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
PE20070461A1 (es) 2005-09-26 2007-05-10 Wyeth Corp Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona como inhibidores de b-secretasa
KR101052122B1 (ko) 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
DE102005057688A1 (de) 2005-12-01 2007-06-14 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums
EP1966185A2 (en) 2005-12-19 2008-09-10 Wyeth a Corporation of the State of Delaware 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION
EP1974278A4 (en) 2005-12-20 2012-01-04 Fieldbus Foundation SYSTEM AND METHOD FOR IMPLEMENTING INSTRUMENTED SAFETY SYSTEMS
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2644600B1 (en) 2006-06-12 2017-01-11 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
RU2429222C2 (ru) 2006-07-18 2011-09-20 Астеллас Фарма Инк. Аминоиндановое производное или его соль
US20100298342A1 (en) 2006-09-07 2010-11-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
CL2008000784A1 (es) 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
PE20090617A1 (es) 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
EP2077637B1 (en) 2007-12-12 2020-03-11 Alcatel Lucent System and method for protecting payload information in radio transmission
AU2009216825A1 (en) 2008-02-18 2009-08-27 F. Hoffmann-La Roche Ag 4, 5-dihydro-oxazol-2-yl amine derivatives
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CN102209721A (zh) 2008-09-11 2011-10-05 安姆根有限公司 作为β-分泌酶调节剂的螺四环化合物及其使用方法
CA2743584A1 (en) * 2008-11-23 2010-05-27 Pfizer Inc. Lactams as beta secretase inhibitors
MX2011009571A (es) * 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
WO2011106414A1 (en) 2010-02-24 2011-09-01 Dillard Lawrence W Inhibitors of beta-secretase
AR080865A1 (es) 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β-分泌酶抑制劑

Similar Documents

Publication Publication Date Title
JP2015511958A5 (OSRAM)
HRP20160415T1 (hr) Inhibitori beta-sekretaze
MX2017013483A (es) Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1).
JP2013525444A5 (OSRAM)
RU2014145682A (ru) Органические соединения
JP2016513130A5 (OSRAM)
EP4275748A3 (en) Compositions and methods for treating cns disorders
JP2015501783A5 (OSRAM)
EP4616908A3 (en) Oxysterols and methods of use thereof
JP2014507455A5 (OSRAM)
JP2020502092A5 (OSRAM)
JP2016535786A5 (OSRAM)
CL2018000036A1 (es) Derivados etinilo
JP2015537020A5 (OSRAM)
JP2012521994A5 (OSRAM)
JP2015500223A5 (OSRAM)
JP2013032389A5 (OSRAM)
JP2016503010A5 (OSRAM)
JP2017514910A5 (OSRAM)
JP2014500861A5 (OSRAM)
JP2016510326A5 (OSRAM)
JP2015500257A5 (OSRAM)
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
JP2013523846A5 (OSRAM)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий